Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Jenscare Scientific Co. Ltd. Class H ( (HK:9877) ) has provided an announcement.
Jenscare Scientific has submitted a registration application for CE marking of its JensClip transcatheter mitral valve repair system, marking another step in its globalization push following the earlier CE application for its LuX-Valve Plus tricuspid replacement device. JensClip, a globally patented device designed to treat severe mitral regurgitation, features a claw‑wedge mechanical locking design for secure fixation, a diamond‑shaped clip for easier retrieval and repositioning, and an integrated release mechanism to shorten procedure time and enhance safety, with one‑year clinical follow‑up data presented at major international cardiology conferences showing strong safety and efficacy performance. The product is currently under registration review with China’s National Medical Products Administration and has already been used in overseas clinical practice, positioning the company to tap broader clinical demand if regulatory approvals and eventual commercialization are achieved.
More about Jenscare Scientific Co. Ltd. Class H
Jenscare Scientific Co., Ltd. is a China-based medical device company specializing in innovative structural heart disease therapies, including transcatheter valve repair and replacement systems. Its product portfolio targets severe cardiac valve conditions such as mitral and tricuspid regurgitation, with a strategic focus on both the domestic Chinese market and international expansion through regulatory approvals in major markets.
Average Trading Volume: 608,282
Technical Sentiment Signal: Buy
Current Market Cap: HK$5.18B
For a thorough assessment of 9877 stock, go to TipRanks’ Stock Analysis page.